SC 13G 1 hbio13g.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. )* HARVARD BIOSCIENCE INC -------------------------------------------------------------------- (Name of Issuer) Common Stock ------------------------------------------------------------------ (Title of Class of Securities) 416906105 ---------------------------------------------------------------------- (CUSIP Number) 12/16/2022 ---------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedule is filed: /X/ Rule 13d-i(b) / / Rule 13d-i(c) / / Rule 13d-i(d) ------------------------ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. CUSIP NO. 416906105 13G ------------------------------------------------------------------------ -------- 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) AMH Equity LLC ------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / ------------------------------------------------------------------------ 3 SEC USE ONLY ------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION New York, USA ------------------------------------------------------------------------ NUMBER OF 5 SOLE VOTING POWER SHARES 136,941 BENEFICIALLY -------------------------------------------------- OWNED BY 6 SHARED VOTING POWER EACH ------------------------------------------------- REPORTING 7 SOLE DISPOSITIVE POWER PERSON 136,941 WITH ------------------------------------------------- 8 SHARED DISPOSITIVE POWER ------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,253,907 shares of common stock. ------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / ------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.41% ------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* PN ------------------------------------------------------------------------ CUSIP NO. 416906105 13G ------------------------------------------------------------------------ 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Leviticus Partners, L.P. ------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / ------------------------------------------------------------------------ 3 SEC USE ONLY ------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, USA ------------------------------------------------------------------------ NUMBER OF 5 SOLE VOTING POWER SHARES 2,116,966 Shares of Common Stock BENEFICIALLY ------------------------------------------ OWNED BY 6 SHARED VOTING POWER EACH ----------------------------------- REPORTING 7 SOLE DISPOSITIVE POWER PERSON 2,116,966 Shares of Common Stock WITH --------------------------------------------- 8 SHARED DISPOSITIVE POWER ------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,253,907 shares of common stock. ------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / ------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.41% ------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* IA ------------------------------------------------------------------------ ITEM 1: (a) NAME OF ISSUER: HARVARD BIOSCIENCE INC (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 84 October Hill Road Holliston MA 01746 ITEM 2: (a) NAME OF PERSON FILING: This Schedule 13G is jointly filed by Leviticus Partners, L.P., a Delaware limited partnership ("Leviticus"), and AMH Equity, LLC ("AMH"), a New York limited liability company (each a "Reporting Person" and, collectively, the "Reporting Persons"). AMH is the general partner of Leviticus. (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE : 745 Fifth Avenue Suite 500 New York, NY 10151 (c) CITIZENSHIP: See above (d) TITLE OF CLASS OF SECURITIES: SEE COVER PAGE (e) CUSIP NUMBER: SEE COVER PAGE ITEM 3: See Item 12 above ITEM 4: (a) AMOUNT BENEFICIALLY OWNED: See Item 9 above (b) PERCENT OF CLASS: See Item 11 above (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS VOTING AND DISPOSITIVE POWERS: See Items 5 and 7 above ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: / / ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: N/A The principal address of Leviticus is: 745 Fifth Avenue Suite 500 New York, NY 10151 ITEM 7: Inapplicable ITEM 8: Inapplicable ITEM 9: NOTICE OF DISSOLUTION OF GROUP: Inapplicable ITEM 10: CERTIFICATION: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in theordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: December 21, 2022 Leviticus Partners, L.P. By: AMH Equity, LLC, its general partner By: /s/ Adam Hutt Name: Adam Hutt Title: Managing Member AMH Equity, LLC By: /s/ Adam Hutt Name: Adam Hutt Title: Managing Member

SEC Form SC 13G filed by Harvard Bioscience Inc.